Literature DB >> 16387510

Imaging vascular physiology to monitor cancer treatment.

George R Laking1, Catharine West, David L Buckley, Julian Matthews, Patricia M Price.   

Abstract

The primary physiological function of the vasculature is to support perfusion, the nutritive flow of blood through the tissues. Vascular physiology can be studied non-invasively in human subjects using imaging methods such as positron emission tomography (PET), magnetic resonance imaging (MRI), X-ray computed tomography (CT), and Doppler ultrasound (DU). We describe the physiological rationale for imaging vascular physiology with these methods. We review the published data on repeatability. We review the literature on 'before-and-after' studies using these methods to monitor response to treatment in human subjects, in five broad clinical settings: (1) antiangiogenic agents, (2) vascular disruptive agents, (3) conventional cytotoxic drugs, (4) radiation treatment, and (5) agents affecting drug delivery. We argue that imaging of vascular physiology offers an attractive 'functional endpoint' for clinical trials of anticancer treatment. More conventional measures of tumour response, such as size criteria and the uptake of fluorodeoxyglucose, may be insensitive to therapeutically important changes in vascular function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16387510     DOI: 10.1016/j.critrevonc.2005.10.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  13 in total

1.  CT and MRI findings correlate with the time-course of unresectable cavernous haemangioma of the liver after fractionated radiotherapy.

Authors:  H-L Lee; T-S Chung; S-W Chen; W T Lao
Journal:  Br J Radiol       Date:  2012-03       Impact factor: 3.039

Review 2.  Radionuclide imaging of perfusion and hypoxia.

Authors:  George Laking; Pat Price
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

3.  MRI of blood-brain barrier permeability in cerebral ischemia.

Authors:  Quan Jiang; James R Ewing; Michael Chopp
Journal:  Transl Stroke Res       Date:  2012-03       Impact factor: 6.829

Review 4.  Molecular and functional MRI of the tumor microenvironment.

Authors:  Marie-France Penet; Kristine Glunde; Michael A Jacobs; Arvind P Pathak; Zaver M Bhujwalla
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

5.  High and low frequency subharmonic imaging of angiogenesis in a murine breast cancer model.

Authors:  Manasi Dahibawkar; Mark A Forsberg; Aditi Gupta; Samantha Jaffe; Kelly Dulin; John R Eisenbrey; Valgerdur G Halldorsdottir; Anya I Forsberg; Jaydev K Dave; Andrew Marshall; Priscilla Machado; Traci B Fox; Ji-Bin Liu; Flemming Forsberg
Journal:  Ultrasonics       Date:  2015-05-05       Impact factor: 2.890

6.  Novel agents in renal carcinoma: a reality check.

Authors:  Yana G Najjar; Brian I Rini
Journal:  Ther Adv Med Oncol       Date:  2012-07       Impact factor: 8.168

7.  Dynamic contrast enhanced fluorescent molecular imaging of vascular disruption induced by combretastatin-A4P in tumor xenografts.

Authors:  Li Liu; Xing Su; Ralph P Mason
Journal:  J Biomed Nanotechnol       Date:  2014-08       Impact factor: 4.099

8.  PET Imaging of Angiogenesis.

Authors:  Gang Niu; Xiaoyuan Chen
Journal:  PET Clin       Date:  2009-01-01

9.  The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.

Authors:  Flemming Forsberg; Raymond J Ro; Andrew Marshall; Ji-Bin Liu; See-Ying Chiou; Daniel A Merton; Priscilla Machado; Adam P Dicker; Levon N Nazarian
Journal:  Mol Imaging       Date:  2014       Impact factor: 4.488

Review 10.  Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.

Authors:  Ramasamy Paulmurugan; Bryan Oronsky; Chad F Brouse; Tony Reid; Susan Knox; Jan Scicinski
Journal:  Theranostics       Date:  2013-05-25       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.